8 Best Life Sciences Penny Stocks to Buy
On March 11, CBRE shared an analysis covering the U.S. market trends in life sciences real estate.
Pacific Biosciences Of California Inc. (PACB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 37,264,228 | $69,684,106 | +21% | 0.46% |
| 2. | SOFTBANK GROUP CORP Masayoshi Son | 20,451,570 | $38,244,436 | 0.25% | |
| 3. | D E Shaw D. E. Shaw | 4,438,273 | $8,299,571 | 0% | |
| 4. | Millennium Management Israel Englander | 4,344,569 | $8,124,344 | -12% | 0% |
| 5. | Casdin Capital Eli Casdin | 4,223,767 | $7,898,444 | +484% | 0.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.40 | 40,000 | $176,160.00 | 40,000 | 2024-03-06 | Filing | |
| $2.01 | 1 | $2.01 | 215,156 | 2018-09-01 | Filing | |
| $2.01 | 5,989 | $12,013.93 | 215,155 | 2018-03-01 | Filing | |
| $4.07 | 3,244 | $13,207.95 | 194,166 | 2017-09-01 | Filing | |
| $4.07 | 3,212 | $13,077.66 | 190,922 | 2017-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.37 | 88,185 | $120,813.45 | 1,245,663 | 2026-04-01 | Filing | |
| $1.51 | 12,497 | $18,920.46 | 3,581,813 | 2026-03-03 | Filing | |
| $1.51 | 6,504 | $9,847.06 | 2,243,634 | 2026-03-03 | Filing | |
| $1.51 | 2,979 | $4,510.21 | 305,948 | 2026-03-03 | Filing | |
| $1.63 | 55,107 | $89,769.30 | 1,742,638 | 2026-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 951,055 | $1,255,393 | 0.46% | |
| 2. | 604,884 | $798,447 | 0.11% | |
| 3. | 182,618 | $241,056 | 0.24% | |
| 4. | 142,057 | $187,515 | 0.01% | |
| 5. | 93,319 | $123,181 | 0.02% |
News See All
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2025 Earnings Call Transcript February 12, 2026Pacific Biosciences of California, Inc. beats earnings expectations.
Barclays Analyst Is Bullish On Pacific Biosciences of California, Inc. (PACB)
On December 15, TheFly published that Luke Sergott, a Barclays analyst, lifted the price objective for Pacific Biosciences of California, Inc.
12 Best Genomics Stocks to Invest In
Companies that study DNA to improve people's lives are known as genomics stocks.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2025 Earnings Call Transcript November 5, 2025Pacific Biosciences of California, Inc. beats earnings expectations.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the PacBio Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
Pacific Biosciences (PACB) Jumps 6.5% Ahead of Earnings
According to the company, it is scheduled to announce the results of its financial and operating highlights after market close on August 7, where investors will closely watch out for updates on its restructuring...
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript May 8, 2025Pacific Biosciences of California, Inc. beats earnings expectations.
Hedge Fund Resource Center